The pharmaceutical lobby has initiated several lawsuits against the Trump administration regarding new policies aimed at reducing Medicare drug prices, including a most-favored-nation pricing model. As the administration finalizes plans for mandatory price reductions in Medicare Part B, major drug manufacturers are responding by contesting these regulatory changes in court. The Pharmaceutical Research and Manufacturers of America (PhRMA) is at the forefront of these legal challenges, arguing that such policies could harm patients and infringe on executive powers. Despite claims from the White House about significant savings for Medicaid, details remain unclear, leading to skepticism about the projected impacts of these reforms.